Indianapolis: Eli Lilly and Company and Verve Therapeutics have announced a definitive agreement for Lilly to acquire Verve ...

Verve's leading programs aim to deliver lifelong cardiovascular risk reduction with a single dose by targeting genes strongly linked to cardiovascular disease Lilly's established capabilities in ...

Eli Lilly agreed to acquire Verve Therapeutics for approximately $1 billion up front, adding a potential treatment for ...

Lilly has struck multiple partnership deals with gene-editing companies in the last two years to expand its portfolio beyond ...

U.S. stock index futures declined amid the ongoing Israel-Iran conflict, affecting global markets. Investor focus remains on ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

Eli Lilly will acquire gene-editing startup Verve Therapeutics for up to $1.3 billion, the companies said on Tuesday, sending ...

Eli Lilly will acquire Verve Therapeutics for up to $1.3 billion, the companies said on Tuesday. Verve is developing ...

The rumored acquisition represents a natural progression of the existing partnership between Eli Lilly and Verve Therapeutics that began in mid-2023. Initially focused on advancing Verve’s in vivo ...

The UK must provide better funding opportunities for research and development across the regions if ambition is going to be ...

When Eli Lilly snapped up Scorpion Therapeutics' PI3Kα program earlier this year, the deal allowed Scorpion to spin out a new ...

Eli Lilly and Company (NYSE:LLY) is one of the best stocks to buy for beginners now. On June 11, Eli Lilly announced a ...